Stocks Health care IMNN
NASDAQ · Health careImunon, Inc. (IMNN)
It posted a net loss of $14.7M. In fiscal 2025 capital spending exceeded operating cash flow by $14.2M. At June 30, 2026 it held $6.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Key facts about Imunon, Inc.
- Net worth
- Imunon, Inc. has a market value (market cap) of $4.3M at the latest share price, and shareholders' equity of $4.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2022 revenue was $500K (0.0% year on year), with a net loss of $35.9M.
- Cash flow
- In fiscal 2025 operations used $13.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Imunon, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Imunon, Inc. does
Imunon, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker IMNN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$14.5M | -$6.83 | -$14.2M |
| 2024 | n/a | -$18.6M | -$16.94 | -$18.9M |
| 2023 | n/a | -$19.5M | -$22.59 | -$19.5M |
| 2022 | $500K | -$35.9M | -$52.60 | -$23.4M |
| 2021 | $500K | -$20.8M | -$40.05 | -$16.5M |
| 2020 | $500K | -$21.5M | -$105.40 | -$15.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Imunon, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 29, 2026Material agreement8-KImunon entered into an exchange agreement to convert $1,200,000 of its promissory note into Series B Preferred Stock.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026
- August 11, 2026
- August 11, 2026
- June 30, 2026
- June 17, 2026
- June 16, 2026
- June 4, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Imunon, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $7.9K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 25, 2026 | Faller Douglas VincentChief Medical Officer | Received as pay | 4,390 | $6.2K |
| September 25, 2026 | Lindborg StacyPresident and CEO, Director | Received as pay | 6,697 | $9.4K |
| September 25, 2026 | Tardugno Michael HExecutive Chairman of Board, Director | Received as pay | 7,169 | $10.1K |
| September 11, 2026 | Faller Douglas VincentChief Medical Officer | Received as pay | 4,211 | $6.2K |
| September 11, 2026 | Lindborg StacyPresident and CEO, Director | Received as pay | 5,504 | $8.1K |
| September 11, 2026 | Tardugno Michael HExecutive Chairman of Board, Director | Received as pay | 5,824 | $8.6K |
| August 31, 2026 | Eylward SusanGeneral Counsel and Corp Sec | Sold | 2,525 | $3.9K |
| August 28, 2026 | Eylward SusanGeneral Counsel and Corp Sec | Received as pay | 2,525 | $4K |
Who owns IMNN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Armistice Capital, LLC13G, passive with 1 related filers | 9.99% | August 14, 2026 |
Largest institutional holders
Insiders
8 insiders reported holding 339,195 shares in total, about $261.2K at the last price.
| Holder | Shares |
|---|---|
| Lindborg StacyPresident and CEO, Director | 113,197 |
| Tardugno Michael HExecutive Chairman of Board, Director | 103,921 |
| Faller Douglas VincentChief Medical Officer | 45,678 |
| Dentzer James EDirector | 21,897 |
| Fritz Frederick J.Director | 21,031 |
| Braun Donald PDirector | 15,499 |
| Pellizzari Christine ADirector | 15,076 |
| Eylward SusanGeneral Counsel and Corp Sec | 2,896 |
Questions about IMNN
What does Imunon, Inc. do?
Imunon, Inc. is a company in the Health care sector, listed on NASDAQ as IMNN. Its shares trade on NASDAQ under the ticker IMNN.
What is Imunon, Inc.'s net worth?
Imunon, Inc. has a market value (market cap) of $4.3M at the latest share price, and shareholders' equity of $4.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Imunon, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $14.7M.
When did Imunon, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 29, 2026.
When is Imunon, Inc.'s next earnings report?
Imunon, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare IMNN with
Follow IMNN
Get an email when Imunon, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Imunon, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.